KRAS and lung carcinoma: The KRAS genetic variants are significant in lung cancer, especially in LUAD; the G12D mutation corresponds to ~ 3% of patients [109], and therefore a similar targeted TCR T therapy can bring a sea change in lung cancer treatment.